Skip to main content

Table 2 Increased OR values in the Interphone studies on relationships between MP use and head tumours.

From: Mobile phones and head tumours. The discrepancies in cause-effect relationships in the epidemiological studies - how do they arise?

Author (tumour type)

year

ref.

years MP use

total tumours cases/controls and OR (95%CI)

ipsilateral tumours cases/controls and OR (95%CI)

contralateral tumours cases/controls and OR (95%CI)

Lonn et al.

2004

40

since ≥ 10

14/29

1.9 (0.9-4.1)

12/15

3.9 (1.6-9.5)

4/17

0.8 (0.2-2.9)

(acoustic neuromas)

  

for ≥ 10

11/26

1.6 (0.7-3.6)

9/12

3.1 (1.2-8.4)

4/16

0.8 (0.2-3.1)

Schoemaker et al. 2005

 

43

since ≥ 10

47/212

1.0 (0.7-1.5)

31/124

1.3 (0.8-2.0)

20/105

1.0 (0.6-1.7)

(acoustic neuromas)

  

for ≥ 10

31/131

1.1 (0.7-1.8)

23/72

1.8 (1.1-3.1)

12/73

0.9 (0.5-1.8)

Lonn et al.

2005

41

since ≥ 10

25/38

0.9 (0.5-1.5)

15/18

1.6 (0.8-3.4)

11/25

0.7 (0.3-1.5)

(gliomas)

  

for ≥ 10

22/33

0.9 (0.5-1.6)

14/15

1.8 (0.8-3.9)

9/23

0.6 (0.3-1.4)

(meningiomas)

  

since ≥ 10

12/36

0.9 (0.4-1.9)

5/18

1.3 (0.5-3.9)

3/22

0.5 (0.1-1.7)

   

for ≥ 10

8/32

0.7 (0.3-1.6)

4/15

1.4 (0.4-4.4)

3/23

0.5 (0.1-1.8)

Hepworth et al.

2006

46

since ≥ 10

66/112

0.9 (0.6-1.3)

    

(gliomas)

  

for ≥ 10

48/67

1.14 (0.74-1.73)

    
   

regular use

  

278/486

1.24 (1.02-1.52)

199/491

0.75 (0.61-0.93)

Schuz et al.

2006

47

females only ≥ 0.5

30/38

1.96 (1.1-3.5)

    

(gliomas)

         

Lonn et al.

2006

48

since ≥ 10

7/15

1.4 (0.5-3.9)

6/9

2.6 (0.9-7.9)

1/9

0.3 (0.0-2.3)

(parotid gland tumours)

  

for ≥ 10

5/13

1.1 (0.4-3.6)

4/8

2.0 (0.5-7.0)

1/8

0.3 (0.0-2.6)

Klaeboe et al.

2007

49

since ≥ 6

70/73

0.8 (0.5-1.2)

39/37

1.3 (0.8-2.1)

32/42

0.8 (0.5-1.4)

(gliomas)

  

for ≥ 6

55/61

0.7 (0.4-1.2)

30/30

1.2 (0.7-2.1)

27/34

0.9 (0.5-1.5)

Lahkola et al.

2007

50

since ≥ 10

143/220

0.95 (0.74-1.23)

77/117

1.39 (1.01-1.92)

67/121

0.98 (0.71-1.37)

(gliomas)

  

for ≥ 10

88/134

0.94 (0.69-1.78)

43/74

1.14 (0.76-1.72)

41/71

1.01 (0.67-1.53)

Lahkola et al.

2008

54

since ≥ 10

73/212

0.91 (0.67-1.25)

33/113

1.05 (0.67-1.65)

24/117

0.62 (0.38-1.03)

(meningiomas)

  

for ≥ 10

42/130

0.85 (0.57-1.26)

21/73

0.99 (0.57-1.73)

13/68

0.64 (0.33-1.23)

Interphone

2010

72

≥ 1640 calls

160/113

1.82 (1.15-2.89)

100/62

1.96 (1.22-3.16)

39/31

1.25 (0.64-2.42)

(gliomas)

         

Sadetzki et al.

2008

53

> 5479 calls

86/157

1.13 (0.79-1.61)

121/159

1.58 (1.11-2.24)

46/135

0.78 (0.51-1.19)

(parotid gland tumours)

  

> 266.3 hours

80/155

1.03 (0.72-1.47)

115/158

1.49 (1.05-2.13)

48/129

0.84 (0.55-1.28)

   

> 5479 calls <5-year latency

47/82

1.16 (0.74-1.82)

35/40

1.80 (1.05-3.10)

12/41

0.63 (0.31-1.30)

"

 

> 5479 calls >5-year latency

120/215

1.08 (0.77-1.50)

86/119

1.50 (1.03-2.20)

34/94

0.84 (0.52-1.34)

only regular users

> 5479 calls

86/157

1.48 (1.05-2.10)

    

"

> 18997 calls

81/140

1.51 (1.05-2.17)

    

"

> 1035 cumulative calls

83/134

1.50 (1.04-2.16)

    
   

≥ 18997 calls, urban areas

49/99

1.00 (0.65-1.55)

    
   

" rural areas

32/41

1.81 (1.04-3.14)

    
   

≥ 1035 hours, urban areas

51/96

1.02 (0.67-1.58)

    
   

" rural areas

32/38

1.96 (1.11-3.44)

    
  1. 95% s.s. data